Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ar9281. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 known ✓ | P34913 | 17/20 | 1.00 |
| ▸ | EPHX1 | P07099 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ar9281 SCHEMBL18464997 | 1.00 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL4009896 | 0.95 | EPHX2 (0.90) | EPHX2EPHX1 | |
| SCHEMBL22451032 | 0.92 | EPHX2 (0.85) | EPHX2EPHX1 | |
| SCHEMBL4116139 | 0.90 | EPHX2 (0.81) | EPHX2EPHX1 | |
| SCHEMBL4010114 | 0.90 | EPHX2 (0.81) | EPHX2EPHX1 | |
| SCHEMBL27778386 | 0.90 | EPHX2 (0.81) | EPHX2EPHX1 | |
| SCHEMBL4128628 | 0.90 | EPHX2 (0.81) | EPHX2EPHX1 | |
| SCHEMBL27778382 | 0.90 | EPHX2 (0.81) | EPHX2EPHX1 | |
| SCHEMBL15335286 | 0.89 | EPHX2 (0.80) | EPHX2EPHX1 | |
| SCHEMBL4010055 | 0.88 | EPHX2 (0.79) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 240 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-14 | — | — | US | claimed |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-12-02 | — | — | US | claimed |
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2024-03-14 | — | — | US | claimed |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | KADDURAH DAOUK RIMA F (US) | 2023-11-23 | — | — | US | claimed |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | CHIBA UNIVERSITY (JP) | 2023-09-28 | — | — | US | claimed |
| US-11723929-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | claimed |
| US-11690837-B2 | Methods of improving cell-based therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-04 | — | — | US | claimed |
| US-20230071934-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-03-09 | — | — | US | claimed |
| US-11564914-B2 | Methods of treating bone loss | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-31 | — | — | US | claimed |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | claimed |
| WO-2009129501-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | WO | claimed |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. | 2009-10-01 | — | — | US | claimed |
| US-20090216318-A1 | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-08-27 | — | — | US | claimed |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC | 2009-08-06 | — | — | US | claimed |
| EP-2077839-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | Arete Therapeutics, INC. (US) | 2009-07-15 | — | — | EP | claimed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| US-20080221105-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | claimed |
| US-20080221104-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | claimed |
| WO-2008094869-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| WO-2008058033-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | ARETE THERAPEUTICS, INC. (US) | 2008-05-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082211-A1 | SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR OCULAR DISEASES | EPHX1, ALDH1A2, EPHX2 | EPHX2 3/4885EPHX1 1/4885 |
| US-20230301949-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | FABP7, ADH1B, ELOVL1 | EPHX2 51/4885EPHX1 25/4885 |
| US-20090247521-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | EPHX1, ECE1, LIPG | EPHX2 5/4885EPHX1 1/4885 |
| US-11723929-B2 | Methods of improving cell-based therapy | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885EPHX1 1/4885 |
| US-20220202744-A1 | METHODS OF TREATING MENTAL DISORDERS | FAAH, EPHX1, FAAH2 | EPHX2 4/4885EPHX1 2/4885 |
| US-20260130877-A1 | TREATMENT OF NEURODEVELOPMENTAL DISORDERS | EED, ICOS, FABP7 | EPHX2 10/4885EPHX1 8/4885 |
| US-11690837-B2 | Methods of improving cell-based therapy | ELOVL1, ELOVL3, IL2 | EPHX2 127/4885EPHX1 116/4885 |
| US-11564914-B2 | Methods of treating bone loss | EPHX1, NCEH1, SOST | EPHX2 4/4885EPHX1 1/4885 |
| US-20230071934-A1 | NOVEL USES | SMPD1, PDE4A, PDE7A | EPHX2 534/4885EPHX1 337/4885 |
| US-20080221105-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | EPHX1, NCEH1, PNLIP | EPHX2 6/4885EPHX1 1/4885 |
| US-12485107-B2 | Methods for the prevention or treatment of cytokine storm | TNF, PTGES2, IL2 | EPHX2 13/4885EPHX1 5/4885 |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | EPHX1, NCEH1, PNLIP | EPHX2 6/4885EPHX1 1/4885 |
| US-20230375561-A1 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | SLC25A20, CPT2, NDUFAB1 | EPHX2 1139/4885EPHX1 657/4885 |
| US-20080221104-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS | EPHX1, EPHX2, LTA4H | EPHX2 2/4885EPHX1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.